Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Renalytix ( (GB:RENX) ) has issued an update.
Renalytix announced it will release its unaudited interim results for the six months ending December 31, 2024, on March 18, 2025. The company is hosting both online and in-person investor presentations to discuss these results, inviting current shareholders and interested investors to participate. The announcement underscores the company’s commitment to transparency and engagement with stakeholders, as well as its strategic focus on expanding the deployment of kidneyintelX.dkd across the U.S. healthcare system.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment of chronic kidney disease, which is commercially available in the United States.
YTD Price Performance: 13.75%
Average Trading Volume: 404
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $38.56M
Find detailed analytics on RENX stock on TipRanks’ Stock Analysis page.